Navigation Links
The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Date:2/22/2010

ST. JOSEPH, Mich., Feb. 22 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that the Medical Biochemistry group at the Academic Medical Center, University of Amsterdam will join the MetaMiner Metabolic Diseases project from GeneGo. The MetaMiner program is focused on the fundamental understanding of human diseases at the level of disease pathways and causative gene-disease associations supported by a repository of OMICs data. Ongoing MetaMiner projects include Oncology, CNS, Cystic fibrosis and Stem cells.

"GeneGo provides unique, innovative reconstructions of disease pathways that are fundamentally important and required for the understanding of disease processes so we can find cures," said Milka Sokolovic, PhD, Medical Biochemistry, Academic Medical Center, Amsterdam. "We want to be a part of this innovation to have access to high quality resources to build pathways we need for our research programs that we will use to publish."

"The University of Amsterdam group is well known for their research on nutrition and fasting and we really welcome Milka's expertise in this area," said Julie Bryant, GeneGo's VP of Business Development. "This will be the first 'systems analysis' platform devoted specifically for metabolic diseases. We will start with the 'usual suspects' of type 2 diabetes and obesity and then move to other human diseases which significantly affect metabolism."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.1, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.1 is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

SOURCE GeneGo, Inc.

Back to top

RELATED LINKS
http://www.genego.com

'/>"/>

SOURCE GeneGo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. New Canadian solar photovoltaic research network established; based at McMaster University
2. Beike Biotechnology, Jiangsu University and Nanjing Drum Tower Hospital Receive $1.8 Million for Human Mesenchymal Stem Cell R&D and Clinical Trials
3. Hahnemann University Hospital Granted Magnet(R) Status
4. Indiana Industry, University and Community Leaders Capitalize on Next Generation of States Life Sciences Growth
5. AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease
6. Nikon Corporation Acquires License From Harvard University For STORM Super Resolution Microscopy -- Will Create Innovative New N-STORM Microscope
7. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
8. iSirona Announces Go-live at University Hospitals in Cleveland
9. Arts Way Manufacturing Announces Contract for Modular Swine Facility for the University of Georgia
10. WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGens SmartChip(TM) High-throughput Real-Time PCR System
11. New Program to Bring University of Florida Incubator Companies Millions in New Contracts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... , Feb. 20, 2017  Atrius Health and ... entered into an agreement to develop a cloud ... By providing a holistic view of the multiple ... Watson Cognitive Insights could be designed to support ... Health is an innovative nonprofit healthcare organization with ...
(Date:2/18/2017)... Feb 17, 2017 Research and Markets has ... Report" report to their offering. ... The report provides separate comprehensive analytics for ... , and Rest of World. Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)...  Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today presented ... drug candidates, PTG-100 and PTG-200, at the 12 ... Colitis Organization (ECCO).  The ECCO congress is being ... from February 15 – 18, 2017. ... drug candidates PTG-100 and PTG-200. PTG-100, a potential ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life Sciences ... development of liquid biopsy tests based on the ... an exclusive license agreement with its first international ... liquid biopsy test for prostate cancer, the Prostate ... . This is the first overseas appointment ...
Breaking Biology Technology:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):